Moetaz Albizem
Publications by Year
Research Areas
Parathyroid Disorders and Treatments, SARS-CoV-2 and COVID-19 Research, Dialysis and Renal Disease Management, Lipoproteins and Cardiovascular Health, Inhalation and Respiratory Drug Delivery
Most-Cited Works
- → Cinacalcet HCl, an Oral Calcimimetic Agent for the Treatment of Secondary Hyperparathyroidism in Hemodialysis and Peritoneal Dialysis(2005)407 cited
- → Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)(2014)357 cited
- → Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE)(2007)154 cited
- → Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl(2005)143 cited
- → Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials(2014)131 cited
- → A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Participants With CKD Not Receiving Dialysis(2008)122 cited
- → Baseline Characteristics of Patients in the Reduction of Events with Darbepoetin Alfa in Heart Failure Trial (RED-HF)(2013)31 cited
- → A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies(2024)5 cited
- → Efficacy and Safety of AMG 145, a Fully Human Monoclonal Antibody to PCSK9: Data from Four Phase 2 Studies in Over 1200 Patients(2013)1 cited
- → 360. A First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies(2023)